Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Syncom Formulations (India) Ltd

SYNCOMF.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Micro Cap Analyst: N/A

Last Close

$0.17

▲ +4.40%

Market Cap $158.53M · Vol 7.20M

Key Metrics

P/E Ratio

17.17

FWD: N/A

Market Cap

$158.53M

Micro Cap

Div Yield

0.62%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

76.11

Momentum

Beta

2.02

vs Market

52W High

$0.20

20.38% below

52W Low

$0.11

55.87% above

Volume

7.20M

Avg 4.53M

P/B

2.33

Price-to-book

ROE

N/A

Return on equity

Free Float

49.43%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Syncom Formulations (India) Ltd (SYNCOMF.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SYNCOMF.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+8.18%

+18.94%

+13.18%

+23.02%

YTD

+13.18%

-7.24%

+58.26%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$52.34M
Net Income	$8.18M
Revenue Growth (YoY)	+7.38%
Gross Margin	40.55%
Operating Margin	14.49%
Net Profit Margin	15.63%
ROE	N/A
ROA · ROIC	21.35% · 20.26%

P/E Ratio	17.17
Forward P/E (FY1)	N/A
PEG Ratio	0.24
P/S	1.99
P/B	2.33
P/FCF	21.48
EPS Growth	N/A
Outstanding Shares	940.00M

Technical Indicators

50-Day SMA	$0.15
200-Day SMA	$0.15
RSI (14)	76.11
Beta	2.02
52-Week High	$0.20
52-Week Low	$0.11

Volume Today	7.20M
Avg Daily Volume (30D)	4.53M
Relative Volume	1.59x
Volatility (10D)	59.31
Volatility (30D)	41.19
Free Float	49.43%

Analyst Consensus

N/A

Current Price $0.17

Mean Target N/A

52W Low$0.11 52W High$0.20

Current

Target

$0.11 $0.20

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S861V6

ISININE312C01025

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co +0.88% JNJ Johnson & Johnson +1.07% ABBV Abbvie Inc +1.20% NVS Novartis AG +1.68% NOVN.S Novartis AG +0.85%

Company Profile

Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the development, manufacturing & sale of pharmaceutical products and services& trading of commodities and renting of properties. The Company manufactures and markets more than 200 pharmaceutical formulation products in various dosage forms, like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections and Dry Vial injections, Dry Syrups, Ointments and Inhalers. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Albendazole Oral Suspension USP 100mg, Cetirizine Oral Solution BP, Clotrimazole Cream USP, Compound Benzoic Acid Ointment BP, and others.